Poolbeg Pharma (LON:POLB) Reaches New 12-Month High – Should You Buy?

Poolbeg Pharma PLC (LON:POLB)’s share price reached a new 52-week high on Wednesday. The company traded as high as GBX 9.30 and last traded at GBX 9.04, with a volume of 1485805 shares traded. The stock had previously closed at GBX 9.

Trending Headlines about Poolbeg Pharma

Here are the key news stories impacting Poolbeg Pharma this week:

• Positive Sentiment: An interim safety review of the POLB 001 TOPICAL clinical trial was positive, with no safety issues requiring changes to the study. The trial will continue as planned, reducing near-term regulatory and execution risk for Poolbeg’s cytokine-release-syndrome (CRS) treatment program. Poolbeg Pharma POLB 001 Trial to Continue Unchanged Following Interim Safety Review
• Positive Sentiment: Reports that the cancer-related trial has been cleared to continue reinforce the message that POLB 001 has passed an important interim safety checkpoint. However, the update is primarily about safety and trial continuation, rather than proof of treatment efficacy. Irish biotech’s cancer drug trial cleared to continue
• Positive Sentiment: Cavendish said the trial progress strengthens its investment case and maintained a 19p price target, substantially above Poolbeg’s recent trading range. This provides an additional bullish signal, although the target remains dependent on successful future clinical development. Poolbeg Pharma trial progress strengthens Cavendish case for 19p target
• Neutral Sentiment: Shore Capital reaffirmed its “house stock” designation for Poolbeg Pharma, indicating continued positive broker interest. The rating is supportive of sentiment but does not represent a new clinical or financial result. Poolbeg Pharma Receives House Stock Rating from Shore Capital Group

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group restated a “house stock” rating on shares of Poolbeg Pharma in a research note on Thursday.

Poolbeg Pharma Stock Down 11.7%

The stock has a market cap of £53.25 million, a PE ratio of -7.42 and a beta of 1.83. The business has a 50 day moving average price of GBX 7.97 and a 200 day moving average price of GBX 6.38.

About Poolbeg Pharma

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.